Celgene's Otezla Is A Big Hit

Image source: Celgene Corporation.

Continue Reading Below

Celgene Corp(NASDAQ: CELG)launched Otezla in 2014 to diversify its revenue stream and by all measures, Celgene's first foray into autoimmune disease has been a success. Second quarter sales of Otezla clocked in at $242 million, up 170% from last year and 24% from Q1. Can Otezla's sales continue to head higher?

Transforming treatment

Psoriasis affects 125 million people worldwide and that makes it a major indication responsible for generating billions of dollars in sales for top drugmakers.

<3>More From Fool.com

Continue Reading Below